Chemoradiation of rectal cancer

Minerva Chirurgica

Volumn 68, Issue 1, 2013, Pages 11-26

  Arrazubi, V ^a   Suarez J ^b   Novas, P ^a   Perez Hoyos M T ^a   Vera, R ^b   Martinez Del Prado P ^a  

^a HOSPITAL DE BASURTO   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Chemoradiation; Neoadjuvant treatment; Rectal neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER STAGING; COLON RESECTION; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; PATHOLOGY; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; RECTUM TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; COLECTOMY; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT CARE TEAM; PROGNOSIS; QUALITY OF LIFE; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84878623460     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
3. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995;181:335-46.
4. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, Van Houwelingen HC et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999;25:368-74. (Pubitemid 29364222)
5. Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Soerensen F, Bone J, Jacobsen NO et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer 1986;58:22-8. (Pubitemid 16093098)
6. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-9. (Pubitemid 18076565)
7. Krook JE, Moertel CG, Gunderson IX, Wieand HS, Collins RT, Beart RW et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
8. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985;312:1465-72.
9. Higgins GA, Humphrey EW, Dwight RW, Roswit B, Lee LE, Jr., Keehn RJ. Preoperative radiation and surgery for cancer of the rectum. Veterans Administration Surgical Oncology Group Trial II. Cancer 1986;58:352-9. (Pubitemid 16058615)
10. Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-14. (Pubitemid 18267703)
11. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. (Pubitemid 46630960)
12. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23. (Pubitemid 44394918)
13. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
14. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
15. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33.
16. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008;113:57-64. (Pubitemid 351976386)
17. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg 2009;249:236-42.
18. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-7.
19. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;23:5644-50.
20. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
21. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246. 693-701. (Pubitemid 350035641)
22. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811-20.
23. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 2000;284:1008-15. (Pubitemid 30659131)
24. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8, 507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
25. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative shortcourse radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23. (Pubitemid 44547018)
26. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D et al. Randomized trial of shortcourse radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol 2012;30:3827-33.
27. Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3:CD004078.
28. Benson A, Catalano P, Meropol N, Giantonio B, Sigurdson E, Hartenson J et al. ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouraci (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients with stage II/III rectal cancer receiving either pre or postoperative radiation/FU. Proceedings of ASCO annual meeting 2006; Abstract No 3526.
29. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
30. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704. (Pubitemid 41007824)
31. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44.
32. Macgregor TP, Maughan TS, Sharma RA. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. J Clin Pathol 2012;65:867-71.
33. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010;8:27.
34. Lee SD, Kim TH, Kim DY, Baek JY, Kim SY, Chang HJ et al. Lymphnode ratio is an independent prognostic factor in patients with rectal cancer treated with preoperative chemoradiotherapy and curative resection. Eur J Surg Oncol 2012;38:478-83.
35. Klos CL, Bordeianou LG, Sylla P, Chang Y, Berger DL. The prognostic value of lymphnode ratio after neoadjuvant chemoradiation and rectal cancer surgery. Dis Colon Rectum 2011;54:171-5.
36. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008;26:303-12.
37. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243:132-9.
38. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008, 95:229-36.
39. Lee JH, Jang HS, Kim JG, Cho HM, Shim BY, Oh ST et al. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision. Ann Surg Oncol 2012;19:1213-21.
40. Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009;27:5131-7.
41. Ceyhan GO, Liebl F, Maak M, Schuster T, Becker K, Langer R et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010;252:797-804.
42. Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol 2006;13:645-50.
43. Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum 2011;54:245-52.
44. Kong M, Hong SE, Choi WS, Kim SY, Choi J. Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors. Cancer Res Treat 2012;44:104-12.
45. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007;109:1750-5. (Pubitemid 46668536)
46. Lin AY, Wong WD, Shia J, Minsky BD, Temple LK, Guillem JG et al. Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. Int J Colorectal Dis 2008;23:243-9.
47. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88.
48. Kim JS, Kim JM, Li S, Yoon WH, Song KS, Kim KH et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006;66:195-200. (Pubitemid 44175651)
49. Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Hausler P et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-8. (Pubitemid 39585955)
50. Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A et al. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010;78:369-75.
51. Paez D, Pare L, Altes A, Sancho-Poch FJ, Petriz L, Garriga J et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fiuorouracil. J Cancer Res Clin Oncol 2010;136:1681-9.
52. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008;14:1060-6. (Pubitemid 351325006)
53. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-88.
54. Roh MS. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proceedings of ASCO annual meeting 2011; Abstract No 3053.
55. Bystrom P, Frodin JE, Berglund A, Wilking N, Glimelius B. Phase I study of LIFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer. Radiother Oncol 2004;70:171-5. (Pubitemid 38353016)
56. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-44.
57. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773-80.
58. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679-87.
59. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7. (Pubitemid 38524883)
60. Nogue M, Salud A, Vicente P, Arrivi A, Roca JM, Losa F et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011;16:614-20.
61. Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012;15:141-50.
62. Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011;6:105.
63. Resch G, De Vries A, Ofner D, Eisterer W, Rabl H, Jagoditsch M et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer-a two stage phase II clinical trial. Radiother Oncol 2012;102:10-3.
64. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007;18:738-44. (Pubitemid 46523279)
65. Weiss C, Arnold D, Delias K, Liersch T, Hipp M, Fietkau R et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-8.
66. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer-is the water getting muddy? Acta Oncol 2010;49:278-86.
67. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:1620-7.
68. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poorrisk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241-8.
69. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28:859-65.
70. Ding P, Weiser MR, Hajj C, Saltz LB, Segal NH, Goodman KA. Induction chemotherapy followed by chemoradiotherapy and TME for high-risk locally advanced rectal cancer. Proceedings of ASCO annual meeting 2011; Abstract No e14059.
71. Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999;3:642-7.
72. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-96. (Pubitemid 41095168)
73. Guillem JG, Diaz-Gonzalez JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA et al. cT3NO rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008;26:368-73. (Pubitemid 351171686)
74. Schrag D, Weiser MR, Goodman KA, Gonen M, Cercek A, Reidy DL et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. Proceedings of ASCO annual meeting 2010; Abstract N°3511.
75. Suarez J, Amat I, Vera R, Balen E, Gomez M, Lera JM. Pathologic response of primary rectal cancer to oxaliplatin-based chemotherapy. Clin Colon Rectal Surg 2011;24:119-24.
76. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012, 99:577-83.
77. Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010;97:580-7.
78. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.
79. Veenhof AA, Bloemena E, Engel AF, Van der Peet DL, Meijer OW, Cuesta MA. The relationship of histological tumor regression grade (TRG) and two different time intervals to surgery following radiation therapy for locally advanced rectal cancer. Int J Colorectal Dis 2009;24:1091-6.
80. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011;254:97-102.
81. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao Juliao GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927-34.